TLTianshu Liu

Tianshu Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tianshu Liu has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Challenges and recommendations for implementation of oncology clinical practice guidelines in China

    by Minzhi Lv, Duanduan Yuan, Yue Suo, Fang Ding, Lijuan Hu, Lei Cao, Yi Wang, Jing Lei, Shenglan Tang, Tianshu Liu

    Summary points: As China’s cancer burden continues to rise and treatment becomes increasingly complex, clinical practice guidelines (CPGs) are crucial to standardising cancer care and supporting clinical decision-making. Over the past decades, China has made substantial progress in developing oncology CPGs, transitioning from expert consensus and international adaptation toward domestically led guideline production. This Policy Forum presents an analysis of the optimisation and implementation of oncology CPGs in China. We argue that the core challenge facing oncology CPGs in China is not a lack of guidelines, but the absence of an integrated governance and implementation ecosystem, and insufficient alignment with local evidence. By situating China's oncology sector within a macro-health-system perspective, this Policy Forum provides a conceptual blueprint for other transition economies experiencing a mismatch between rapid clinical technology scaling and fragmented regulatory governance. We propose a four-part strategic framework: (1) Establishing a national joint clearinghouse and registration system; (2) integrating resource-stratified pathways with locally relevant evidence; (3) expanding free, diversified dissemination channels; and (4) embedding implementation science alongside healthcare financing alignment. Addressing these systemic gaps offers scalable lessons for global health systems aiming to transition from the quantity-driven expansion of clinical guidelines to equity-oriented, system-integrated quality enhancement.

  • Open Access

    Safety Profiles of Immune Checkpoint Inhibitor Strategies in Gastrointestinal Cancers and Their Association With Clinical Outcomes: A Systematic Review and Meta‐Analysis

    by Jing Lei, Yiyi Yu, Qing Liu, Ningping Zhang, Yi Wang, Yating Yang, Tianshu Liu, Minzhi Lv

    Background: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with gastrointestinal cancer (GIC). However, ICI‐associated adverse event (AE) profiles in GIC remain poorly characterized, and whether AE incidence is associated with clinical outcomes is unclear. Methods: Randomized controlled trials (RCTs) were identified through February 2025. Primary outcomes included treatment‐related AEs (TRAEs) and immune‐related AEs (irAEs) (any grade/Grade 3+). Single‐arm random‐effects meta‐analysis pooled AE incidences; risk ratios (RRs) compared toxicity across ICI regimens. Digitized Kaplan–Meier curves reconstructed survival data for pooled analysis and Cox models. Weighted Spearman's tests assessed correlations between AE incidences and median overall survival (OS)/progression‐free survival (PFS). Results: Forty RCTs enrolling 10,233 patients investigated ICI monotherapy, dual‐ICI therapy, and ICI combination regimens. Pooled any‐grade TRAE incidences were 68.0% (monotherapy, 95% CI: 60%–76%, I 2 = 97.4%, p < 0.001), 87.0% (dual therapy, 95% CI: 73%–100%, I 2 = 98.0%, p < 0.001), and 90.0% (combination therapy, 95% CI: 83%–96%, I 2 = 94.6%, p < 0.001). IrAE incidences reached 24.0% (monotherapy, 95% CI: 18%–29%, I 2 = 67.2%, p < 0.05) and 37.0% (combination therapy, 95% CI: 25%–49%, I 2 = 98.8%, p < 0.001). Relative to monotherapy, dual‐ICI therapy elevated any‐grade (RR = 1.28, 95% CI: 1.05–1.55) and grade ≥ 3 TRAEs (RR = 2.71, 95% CI: 1.84–3.99); ICI combination therapy increased any‐grade (RR = 1.32, 95% CI: 1.15–1.51) and grade ≥ 3 TRAEs (RR = 2.98, 95% CI: 2.30–3.87). Any‐grade TRAEs moderately correlated with median OS ( R = 0.46, p < 0.001) and PFS ( R = 0.50, p < 0.001). Any‐grade irAEs strongly correlated with median OS ( R = 0.90, p < 0.001) and moderately with PFS ( R = 0.57, p < 0.001). Conclusion: While AE incidence is high among GIC patients receiving ICIs, most events are low‐grade. Dual‐ICI and ICI‐based combination therapies carry higher TRAE and irAE risks than monotherapy. At the trial level, higher non‐severe irAE incidence correlated with favorable survival outcomes; this exploratory ecological association does not apply to individual patients. Systematic Review Registration: This study was registered on International Platform of Registered Systematic Review and Meta‐analysis Protocols (INPLASY202230144).


  • Open Access

    Pembrolizumab combined with disitamab vedotin in human epidermal growth factor receptor 2-positive metastatic colorectal cancer

    by Xiaojing Xu, Minzhi Lv, Luoyan Ai, Qing Wang, Yuehong Cui, Wei Li, Qing Liu, Xi Tang, Xi Chen, Shan Yu, et al.

    Background: Late-line treatment options for microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) are limited. PD-1 blockade alone has minimal clinical benefit in this population. Human epidermal growth factor receptor 2 (HER2)-targeted therapies represent an emerging strategy for HER2-expressing mCRC. This study evaluated the efficacy and safety of pembrolizumab combined with disitamab vedotin (DV), an anti-HER2 antibody–drug conjugate (ADC), in pretreated patients with HER2-positive mCRC. Methods: This multicenter, single-arm, phase II study enrolled patients with MSS/pMMR, HER2-positive mCRC who received 2 prior lines of systemic therapy. Patients received pembrolizumab 400 mg every 6 weeks plus DV 2.5 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or death. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: Between December 2022 and May 2024, 15 patients (median age 59.0 years; 60.0% male) were enrolled. Fourteen patients (93.3%) had HER2 IHC 3+ expressions, and 2 had received prior anti-HER2 therapy. Two patients achieved partial response (ORR = 13.3%; 95% CI, 1.7%-40.5%). With a median follow-up of 26.7 months, median PFS was 2.9 months (95% CI, 2.3 to not reached). Median OS was not reached (95% CI, 16.7 to NR). The 6-month OS rate was 92.9% (95% CI: 6.9%-80.3%), and the 1-year OS rate was 71.4% (95% CI: 51.3%-99.5%). The most common treatment-related adverse events (TRAEs) included nausea, anorexia, alanine aminotransferase elevation, aspartate aminotransferase elevation, and alopecia. Grade 3-4 TRAEs occurred in 2 patients (14.3%), both neutropenia. Conclusions: Pembrolizumab plus disitamab vedotin showed limited antitumor activity in pretreated HER2-positive mCRC. ClinicalTrials.gov Identifier: NCT05333809


  • Open Access

    Serplulimab/Trastuzumab plus Intensive Triplet DOS Chemotherapy in First-line HER2-positive Advanced Gastric Cancer (ASTRUM): A Multicenter Phase II Trial with Dynamic Multi-Omics Profiling

    by Luoyan Ai, Yan Wang, Xiaolin Lin, Yuehong Cui, Yan Hu, Yong Gao, Song Zheng, Yiyi Yu, Ting Han, Qian Li, et al.

    Outcomes for HER2-positive advanced gastric cancer remain unsatisfactory. This multicenter phase II trial (NCT05311189) pioneered the first exploration of intensive DOS triplet chemotherapy combined with serplulimab and trastuzumab as first-line therapy for untreated HER2-positive advanced gastric adenocarcinoma. Dynamic multi-omics profiling was further performed to identify biomarkers for durable clinical benefit (DCB). Eligible patients received up to eight cycles of triple combination therapy, followed by maintenance serplulimab plus trastuzumab. The primary endpoint was progression‑free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Exploratory analyses comprised longitudinal tumor and peripheral blood transcriptomics, circulating tumor DNA (ctDNA), and multiplex immunofluorescence. Forty patients were enrolled. At a median follow‑up of 16.5 months, median PFS was 15.7 months (95% CI 6.8-24.7). ORR was 97.3%, including two complete responses. The 12‑month OS rate was 80.5% (95% CI 60.0-91.2). Grade 3-4 treatment‑related adverse events occurred in 40% of patients, with no treatment‑related deaths. Baseline DCB tumors were enriched for adaptive immune signatures, including higher densities of tertiary lymphoid structures, T cells, and B cells within the tumor microenvironment and these patients also showed systemic immune activation in peripheral blood. Conversely, non‑durable benefit (NDB) tumors exhibited pronounced angiogenic, myeloid, and fibroblast predominance. Early clearance of ERBB2 copy‑number alterations in ctDNA was associated with prolonged PFS. Collectively, this novel regimen featuring firstly adopted intensive DOS triplet chemotherapy plus serplulimab and trastuzumab yields robust antitumor activity and favorable tolerability. Baseline immune activation, systemic immune awakening and early molecular response jointly predict DCB, whereas angiogenic‑myeloid‑fibroblast features characterize non‑responders.

  • Open Access

    Distinct KRAS mutation subtypes reprogram the tumor microenvironment and shape survival outcomes in colorectal cancer

    by Yutong Liu, Yanjing Zhu, Shan Yu, Xiaojing Xu, Yiyi Yu, Mengxuan Zhu, Zhenghang Xu, Chi Zhang, Haojie Zhou, Huishan Li, et al.

  • Open Access

    Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset

    by Jingyuan Wang, Joanne Xiu, Francesca Battaglin, Hiroyuki Arai, Shivani Soni, Wu Zhang, Richard M. Goldberg, Anthony F. Shields, Axel Grothey, Jimmy J. Hwang, et al.

    Histone-lysine N-methyltransferase 2 (KMT2) family proteins methylate lysine 4 on the histone H3 tail at important regulatory regions in the genome and thereby impart crucial functions through modulating chromatin structures and DNA accessibility. We aimed to identify the molecular profile of KMT2-MT oesophageal cancer (EC) and associations with patient outcomes. In our study, KMT2 mutations were significantly associated with longer immunotherapy-related overall survival (OS) in the esophageal adenocarcinoma (EA) (21.42 vs 13.42 months, HR = 0.66, 95% CI: 0.50–0.88, P = 0.004), but not in the esophageal squamous cell carcinoma (ESCC). KMT2 mutations were significantly associated with microsatellite instability-high and higher tumor mutation burden in both EA and ESCC. KMT2 -MT EA showed significantly higher mutation rates in CIC (13% vs 1.1%), NF1 (12.5% vs 2.2%), FBXW7 (12% vs 3.4%), ATM (11.5% vs 2.6%) and BRCA1 (11.5% vs 1%, all q < 0.05), compared to KMT2 -wildtype (WT) tumors. Meanwhile, no significant mutational differences were observed between KMT2 -MT and WT ESCC. Fat digestion and absorption, cholesterol metabolism and the infiltration of activated B cells were significantly enriched in KMT2 -MT EA compared to KMT2 -WT EA, but these results were not observed in the ESCC. This is the largest study to investigate the distinct molecular landscapes in KMT2-MT EC, characterized by higher tumor mutational burden, an increased frequency of microsatellite instability-high, and gene mutations involved in DNA damage repair and epigenetic regulation.

  • Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors

    by Yanjing Zhu, Chi Zhang, Min Li, Luoyan Ai, Fan Xu, Yiyi Yu, Shan Yu, Xiaojing Xu, Qing Liu, Mengxuan Zhu, et al.

    Despite substantial advances in targeting KRASG12C, tumor acquired resistance to KRASG12C inhibitors (KRASG12Ci) remains a major barrier to progress. Here, we report ATF3-driven asparagine metabolic reprogramming as a key convergence point of KRASG12Ci resistance. Multi-omics profiling of resistant models revealed a chronic activation of the integrated stress response (ISR) and a concomitant upregulation of asparagine synthesis. We found that the ISR-inducible transcription factor ATF3 was upregulated and directly transactivated asparagine synthetase (ASNS), driving asparagine production. Genetic ablation of ATF3 or ASNS restored KRASG12Ci sensitivity, whereas exogenous asparagine reconstituted resistance. This ATF3-ASNS axis was conserved in the patient-derived model of acquired KRASG12Ci resistance. Furthermore, pharmacological inhibition of the upstream ISR kinase PERK synergized with KRASG12Ci to overcome resistance. This study reveals a therapeutically targetable mechanism of asparagine metabolic reprogramming that facilitates KRASG12C inhibitor resistance. The alternative text for this image may have been generated using AI.

  • Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

    by Zhi Peng, Tianshu Liu, Hua Wang, Jufeng Wang, Hongli Liu, Feng Ye, Enxiao Li, Jun Zhang, Baorui Liu, Rongbo Lin, et al.

    MET proto-oncogene amplification (METamp) is associated with poor prognosis in gastric or gastroesophageal junction (G/GEJ) cancer. Currently, effective targeted therapies for G/GEJ cancer harboring METamp remain unavailable, and clinical evidence supporting the use of MET inhibitors in this disease population is limited. Here we report the results of a phase 2 study of savolitinib, an oral MET inhibitor, in patients with METamp G/GEJ cancer. This open-label, multicenter, phase 2 trial in China comprised an exploratory phase and a pivotal phase. Patients with METamp (gene copy number ≥10 for pivotal phase), locally advanced or metastatic G/GEJ cancer that had progressed following ≥1 (≥2 for pivotal phase) prior lines of systemic therapy received savolitinib orally. The primary endpoint was objective response rate (ORR) by independent review committee in the pivotal phase. In total, 110 patients were enrolled and received savolitinib, including 45 in the exploratory phase and 65 in the pivotal phase. Independent review committee-assessed ORR was 32.3% (95% confidence interval 21.2-45.1%) in the pivotal phase, which met the predefined efficacy threshold (lower limit of 95% confidence interval of ORR ≥15%). Among all patients enrolled (n = 110), grade ≥3 treatment-related adverse events were reported in 38 patients (34.5%); one (0.9%) treatment-related death occurred. Savolitinib monotherapy showed encouraging antitumor activities and a tolerable safety profile in heavily treated, later-line METamp G/GEJ cancers, supporting further investigation in randomized controlled trials. ClinicalTrials.gov identifier: NCT04923932 .


  • Open Access

    Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study

    by Bei Xu, Guopei Zhu, Jin Lu, Ximei Zhang, Xiaozhong Chen, Qinjiang Liu, Song Qu, Jia Fan, Tianshu Liu

    Background: To evaluate the outcomes of patients with refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with camrelizumab combined with famitinib following platinum‐based chemotherapy. Methods: In this multicenter, phase 2, single‐arm trial, patients with R/M HNSCC who had documented progression after platinum‐based chemotherapy were administered camrelizumab 200 mg every 3 weeks and famitinib at 20 mg once daily (cohort 1). The primary endpoint was the objective response rate (ORR). The key secondary endpoints included progression‐free survival (PFS), duration of response (DOR), time to objective response (TTR), disease control rate (DCR), overall survival (OS), and safety. Findings: Between August 07, 2020 and June 22, 2022, a total of 20 patients with R/M HNSCC were enrolled. The median age of the patients was 61 years (range, 37–69). The ORR was 35.0% (95% CI, 15.4–59.2) and the DCR was 55.0% (95% CI, 31.5–76.9). The median TTR was 2.23 months (95% CI, 2.0–8.3), the median DOR was 8.0 months (95% CI, 2.2 to not reach), the median PFS was 4.1 months (95% CI, 1.7–10.3), and the median OS was 8.4 months (95% CI, 3.0–17.0), with a median follow‐up duration of 7.2 months (range 0.1 months to 19.6 months). Treatment‐related adverse events (TRAEs) of grade ≥ 3 included decreased white blood cell count (15.0%), hypertension (15.0%), pneumonia (15.0%), and tumor bleeding (15.0%). The most common TRAEs of any grade were decreased white blood cell count (50.0%), anemia (50.0%), hypertension (50.0%), and decreased platelet count (45.0%). Interpretation: In this single‐arm phase II trial, camrelizumab plus famitinib demonstrated encouraging efficacy and a manageable safety profile in patients with refractory R/M HNSCC. These preliminary findings warrant further investigation. Trial Registration: ClinicalTrials.gov identifier: NCT04346381